Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
- 1 May 2006
- journal article
- review article
- Published by Elsevier BV in The International Journal of Biochemistry & Cell Biology
- Vol. 38 (5-6), 845-859
- https://doi.org/10.1016/j.biocel.2005.07.011
Abstract
No abstract availableKeywords
This publication has 158 references indexed in Scilit:
- cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2Genes & Development, 2003
- Muscarinic Receptors Control Postprandial Release of Glucagon-Like Peptide-1: In Vivo and in Vitro Studies in RatsEndocrinology, 2002
- Fatty acid‐induced cholecystokinin secretion and changes in intracellular Ca2+ in two enteroendocrine cell lines, STC‐1 and GLUTagThe Journal of Physiology, 2000
- Glucagon-Like Peptide-1, But Not Glucose-Dependent Insulinotropic Peptide, Regulates Fasting Glycemia and Nonenteral Glucose Clearance in MiceEndocrinology, 2000
- Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1997
- Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequencesFEBS Letters, 1995
- Insulin-promoter-factor 1 is required for pancreas development in miceNature, 1994
- Glucagon‐like peptide 1: A potent glycogenic hormoneFEBS Letters, 1994
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomyDigestive Diseases and Sciences, 1991